Two common misconceptions about multiple sclerosis (MS) are that the disease of the central nervous system affects everyone the same way; and that being diagnosed with the condition guarantees ...

Multiple sclerosis (MS) is thought to be an autoimmune inflammatory disease affecting the central nervous system and peripheral nerves. The cause remains unknown. It can be unpredictable and, in some ...

Multiple sclerosis, or MS, is a disease of the brain and spinal cord. Your immune system attacks the nerve fibers and myelin sheathing around them, which interferes with electrical signals in the ...

Trageting abnormal brain cells linked to chronic inflammation may be key to treating people with progressive forms of MS, a ...

B-cell therapy uses drugs called monoclonal antibodies to attack white blood cells known as B cells that cause nerve damage. The FDA has approved three such drugs for MS. Ocrelizumab (Ocrevus)treats ...

Learn about multiple sclerosis, its symptoms, causes, and treatment options. Understand how early diagnosis helps in managing ...

Muscular dystrophy and multiple sclerosis can affect mobility, breathing, speaking, and muscle control. But they have distinct causes, affect different parts of the body, and have other differences.

Multiple sclerosis (MS) is an autoimmune condition in which the protective insulation surrounding neurons in the brain and spinal cord is erroneously attacked. This can cause a wide variety of serious ...

McArdle sign is related to a diagnosis of MS; however, this sign has been described only twice previously. When defined as a reduction in neck strength >10% with neck flexion, McArdle sign is 100% ...

Medicare Parts A and B, Medicare Advantage (Part C), and Medicare Part D offer various levels of coverage for the costs associated with multiple sclerosis (MS) care, including different types of drugs ...

Zenas Biopharma’s lead autoimmune drug has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study.  | Zenas Biopharma’s lead autoimmune drug ...